Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. (CDTX) Stock Overview
Explore Cidara Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
5.6B
P/E Ratio
-18.63
EPS (TTM)
$-11.20
ROE
-0.60%
CDTX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Cidara Therapeutics, Inc. (CDTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 64.28, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $75.91.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -18.63 and a market capitalization of 5.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.